DK1237854T3 - Pulveriseret form af (S)-2-ethoxy-3-[4-(2-(4-methan sulfonyloxyphenyl)ethoxy)phenyl]propanonsyre - Google Patents

Pulveriseret form af (S)-2-ethoxy-3-[4-(2-(4-methan sulfonyloxyphenyl)ethoxy)phenyl]propanonsyre

Info

Publication number
DK1237854T3
DK1237854T3 DK00983616T DK00983616T DK1237854T3 DK 1237854 T3 DK1237854 T3 DK 1237854T3 DK 00983616 T DK00983616 T DK 00983616T DK 00983616 T DK00983616 T DK 00983616T DK 1237854 T3 DK1237854 T3 DK 1237854T3
Authority
DK
Denmark
Prior art keywords
ethoxy
sulfonyloxyphenyl
methane
phenyl
propanoic acid
Prior art date
Application number
DK00983616T
Other languages
Danish (da)
English (en)
Inventor
Agneta Hallgren
Kristina Roos
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1237854T3 publication Critical patent/DK1237854T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00983616T 1999-12-03 2000-11-29 Pulveriseret form af (S)-2-ethoxy-3-[4-(2-(4-methan sulfonyloxyphenyl)ethoxy)phenyl]propanonsyre DK1237854T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904413A SE9904413D0 (sv) 1999-12-03 1999-12-03 Comminuted form
PCT/SE2000/002381 WO2001040169A1 (en) 1999-12-03 2000-11-29 Comminuted form of (s)-2-ethoxy -3-[4-(2- {4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid

Publications (1)

Publication Number Publication Date
DK1237854T3 true DK1237854T3 (da) 2004-01-12

Family

ID=20417978

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00983616T DK1237854T3 (da) 1999-12-03 2000-11-29 Pulveriseret form af (S)-2-ethoxy-3-[4-(2-(4-methan sulfonyloxyphenyl)ethoxy)phenyl]propanonsyre

Country Status (32)

Country Link
EP (1) EP1237854B1 (is)
JP (1) JP2003515580A (is)
KR (1) KR20020067538A (is)
CN (1) CN1216859C (is)
AR (1) AR029456A1 (is)
AT (1) ATE251131T1 (is)
AU (1) AU766036B2 (is)
BR (1) BR0016135A (is)
CA (1) CA2392029A1 (is)
CO (1) CO5271736A1 (is)
CZ (1) CZ20021839A3 (is)
DE (1) DE60005710T2 (is)
DK (1) DK1237854T3 (is)
EE (1) EE200200284A (is)
ES (1) ES2208444T3 (is)
HK (1) HK1049324B (is)
HU (1) HUP0203692A3 (is)
IL (1) IL149516A0 (is)
IS (1) IS6399A (is)
MX (1) MXPA02005165A (is)
MY (1) MY125099A (is)
NO (1) NO20022591L (is)
NZ (1) NZ518926A (is)
PL (1) PL355372A1 (is)
PT (1) PT1237854E (is)
RU (1) RU2248966C2 (is)
SE (1) SE9904413D0 (is)
SK (1) SK7662002A3 (is)
TR (1) TR200400003T4 (is)
UA (1) UA73959C2 (is)
WO (1) WO2001040169A1 (is)
ZA (1) ZA200203797B (is)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
PL193086B1 (pl) 1997-10-27 2007-01-31 Reddys Lab Ltd Dr Nowe związki tricykliczne i związki pośrednie, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
BR9812770A (pt) 1997-10-27 2000-12-12 Reddy Research Foundation Compostos bicìclicos, processo para seu preparo e composições farmacêuticas contendo os mesmos
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
CZ2001826A3 (cs) 1998-10-29 2001-08-15 Dr. Reddy's Research Foundation Zlepšený způsob přípravy nových antidiabetických prostředků
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
CN101511364B (zh) 2006-09-07 2012-08-15 奈科明有限责任公司 用于糖尿病的治疗组合
WO2008108735A1 (en) 2007-03-08 2008-09-12 Albireo Ab 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease
JP5508258B2 (ja) 2007-06-04 2014-05-28 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ トリアリール化合物および前記化合物を含む組成物
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
CR20160207A (es) 2013-11-05 2016-08-10 Ben Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704873D0 (sv) * 1997-12-23 1997-12-23 Astra Ab Sampling apparatus
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues

Also Published As

Publication number Publication date
AR029456A1 (es) 2003-07-02
DE60005710T2 (de) 2004-08-05
CN1402704A (zh) 2003-03-12
EP1237854B1 (en) 2003-10-01
JP2003515580A (ja) 2003-05-07
HUP0203692A3 (en) 2005-05-30
HUP0203692A2 (hu) 2003-03-28
RU2248966C2 (ru) 2005-03-27
CN1216859C (zh) 2005-08-31
PT1237854E (pt) 2004-02-27
DE60005710D1 (en) 2003-11-06
PL355372A1 (en) 2004-04-19
AU2034801A (en) 2001-06-12
SK7662002A3 (en) 2002-10-08
CA2392029A1 (en) 2001-06-07
ZA200203797B (en) 2003-08-13
NZ518926A (en) 2003-11-28
MY125099A (en) 2006-07-31
HK1049324B (zh) 2004-04-30
UA73959C2 (en) 2005-10-17
NO20022591D0 (no) 2002-05-31
IS6399A (is) 2002-05-28
NO20022591L (no) 2002-05-31
IL149516A0 (en) 2002-11-10
SE9904413D0 (sv) 1999-12-03
ES2208444T3 (es) 2004-06-16
MXPA02005165A (es) 2003-09-25
CZ20021839A3 (cs) 2002-08-14
TR200400003T4 (tr) 2004-02-23
ATE251131T1 (de) 2003-10-15
CO5271736A1 (es) 2003-04-30
WO2001040169A1 (en) 2001-06-07
KR20020067538A (ko) 2002-08-22
EP1237854A1 (en) 2002-09-11
RU2002113169A (ru) 2004-01-20
EE200200284A (et) 2003-08-15
BR0016135A (pt) 2002-08-20
AU766036B2 (en) 2003-10-09
HK1049324A1 (en) 2003-05-09

Similar Documents

Publication Publication Date Title
DK1237854T3 (da) Pulveriseret form af (S)-2-ethoxy-3-[4-(2-(4-methan sulfonyloxyphenyl)ethoxy)phenyl]propanonsyre
DK1237855T3 (da) Krystallinsk form af (S)-2-ethoxy-3-[4-(2-(4-methansulfonyloxyphenyl)ethoxy)phenyl]propansyre
DK2251344T4 (da) Formulering af boronsyreforbindelser
LU92025I2 (fr) Méthanesulfonate d'éthylester d'acide 3-¬(2-{¬4-(hexyloxy-carbonylamino-imino-méthyl)-phénylamino-méthyl}-1-méthyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino-propionique
DK1181036T3 (da) Farmaceutiske sammensætninger af erythropoietin
DK1149090T3 (da) Ny krystallinsk form af kaliumsalt af (S)-omeprazol
PT1084103E (pt) Novo derivado do acido 3-aril-2-hidroxipropionico (i)
IS7014A (is) Sjálf-fleytandi samsetningar af kólesterýl ester flutningspróteinhindrum
DK1232152T3 (da) Forbedret fremgangsmåde til fremstilling af nitrogensubstituerede aminotetraliner
PT1084101E (pt) Novo derivado do acido 3-aril-2-hidroxipropionico (iii)
IS1942B (is) Kristölluð form af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
ATE386501T1 (de) Formulierungen von wachstumshormonen
DK1282596T3 (da) Fremstilling af iminodieddikesyreforbindelser ud fra monoethanolaminsubstrater
IS6215A (is) Að mestu leyti kristallað form af melagatrani
DK1055658T3 (da) Fremstilling af cis-1-{2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphtalen-1-yl)phenoxy]ethyl-pyrrolidin
AU2034601A (en) Crystalline form of 3-(4-(2-(4-tert-butoxycarbonylaminophenyl)ethoxy)phenyl)-(s) 2-ethoxy propanoic acid
NO20002631L (no) Pseudopolymorfe former av 2-[2-[4-(bis(4-fluorfenyl)metyl]-1- piperazinyl]etoksy]eddiksyre dihydroklorid
IS5821A (is) Kristalluð form af ósanetant
NO20043105L (no) Fremgangsmate for fremstilling av 2-(substituert fenyl)-2-hydroksy-etyl-karbamater
DE50012694D1 (de) Verwendung von fettsäurealkanolaminestern
SI1237855T1 (en) Crystalline form of (s)-2 ethoxy-3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl) propanoic acid
IS7056A (is) Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3 [4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxý própansýru og insúlín
AU2001290743A1 (en) Solid salt forms of n-(2-(4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)ethyl)-2-oxo-1-piperidineacetamide
SI1237854T1 (en) Comminuted form of (s)-2-ethoxy -3- 4-(2- 4-methanesulfonyloxyphenyl ethoxy) phenyl) propanoic acid
DK1031262T3 (da) Forbedring af rotorharve